This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
==== 2009–2015 ==== The JWP published its report on elements 113–116 and 118 in 2011. It recognised the JINR–LLNL collaboration as having discovered elements 114 and 116, but did not accept either team's claim to element 113 and did not accept the JINR–LLNL claims to elements 115 and 118. The JINR–LLNL claim to elements 115 and 113 had been founded on chemical identification of their daughter dubnium, but the JWP objected that current theory could not distinguish between superheavy group 4 and group 5 elements by their chemical properties with enough confidence to allow this assignment. The decay properties of all the nuclei in the decay chain of element 115 had not been previously characterised before the JINR experiments, a situation which the JWP generally considers "troublesome, but not necessarily exclusive", and with the small number of atoms produced with neither known daughters nor cross-reactions the JWP considered that their criteria had not been fulfilled. The JWP did not accept the Riken team's claim either due to inconsistencies in the decay data, the small number of atoms of element 113 produced, and the lack of unambiguous anchors to known isotopes. In early 2009, the Riken team synthesised the decay product 266Bh directly in the 248Cm + 23Na reaction to establish its link with 278113 as a cross-bombardment. They also established the branched decay of 262Db, which sometimes underwent spontaneous fission and sometimes underwent the previously known alpha decay to 258Lr.
== Economy == The town is part of the Golden Triangle together with Alderley Edge and Prestbury. It grew in popularity in the Victorian era as a desirable area for wealthy North West (most generally Manchester) merchants to move out to once the railways arrived and connected the towns. Wilmslow is the founding location of sports equipment manufacturer Umbro, which has its headquarters in the area. The town is a key location for Royal London, the mutual financial services company. The Information Commissioner's Office, one of the government's executive agencies, is also based in Wilmslow. However, this organisation has announced that it will relocate to offices in Circle Square, Manchester, on the expiry of the lease at the Wilmslow site in autumn 2026. The UK headquarters of Waters Corporation, an American manufacturer of analytical laboratory instruments, is located on Altrincham Road, at the site of Huntingdon Life Sciences' Stamford Lodge facility, which was demolished in 2012. Wilmslow and its close surroundings are served by several car showrooms of notable marques.; these include Aston Martin, Porsche, Ferrari, Jaguar, Maserati, Land Rover, Bentley, McLaren, Rolls-Royce and Lamborghini. The town's Aston Martin dealership sells the highest number of Aston Martins in the UK; a high demand stimulated largely by the high level of affluence in the town.
Nairobi Half Life (Swahili: Nusu Maisha ya Nairobi) is a 2012 Kenyan drama film directed by David "Tosh" Gitonga. The film was selected as the Kenyan entry for the Best Foreign Language Oscar at the 85th Academy Awards but did not make it to the final shortlist. It was the first time Kenya had submitted a film in this category. At the 33rd Durban International Film Festival, Joseph Wairimu won the award for Best Actor. He also won the Africa Movie Academy Award for Most Promising Actor from the Awards 9th ceremony. It won the most awards at Africa Magic Viewers Choice Awards 2014.
Sources: en.wikipedia.org
==== Comprehensive Cancer Center ==== The standards for Comprehensive Cancer Centers are the most restrictive. These facilities must demonstrate expertise in each of three areas: laboratory, clinical and behavioral and population-based research. Comprehensive Cancer Centers are expected to initiate and conduct early phase, innovative clinical trials and to participate in the NCI's cooperative groups by providing leadership and recruiting patients for trials. Comprehensive Cancer Centers must also conduct activities in outreach and education, and provide information on advances in healthcare for both healthcare professionals and the public. Comprehensive cancer centers may apply for up to $1.5 million per year from the Department of Health and Human Services. These grants fund shared resources to further the goals of the National Cancer Institute. Some of these include the administration of cancer research programs, training activities, core facilities with technology shared by investigators and clinical trial management services.
Siuzdak has hundreds of papers and has authored two books: Mass Spectrometry for Biotechnology (1996) and The Expanding Role of Mass Spectrometry in Biotechnology (2003) as well as The Expanding Role of Mass Spectrometry in Biotechnology 2nd Ed. (2006).
==== 1996 kimchi standard dispute with Japan ==== In 1996, Korea protested against Japanese commercial production of kimchi arguing that the Japanese-produced product (kimuchi, キムチ) was different from kimchi. In particular, Japanese kimchi was not fermented and was more similar to asazuke. Korea lobbied for an international standard from the Codex Alimentarius, an organization associated with the World Health Organization that defines voluntary standards for food preparation for international trade purposes. In 2001, the Codex Alimentarius published a voluntary standard defining kimchi as "a fermented food that uses salted napa cabbages as its main ingredient mixed with seasonings, and goes through a lactic acid production process at a low temperature", but which neither specified a minimum amount of fermentation nor forbade the use of any additives. Following the inclusion of the kimchi standard, kimchi exports in Korea did increase, but so did the production of kimchi in China and the import of Chinese kimchi into Korea.
Sources: en.wikipedia.org
=== Beta-blockers === Many of the common symptoms of hyperthyroidism, such as palpitations, trembling, and anxiety, are mediated by increases in beta-adrenergic receptors on cell surfaces. Beta blockers, typically used to treat high blood pressure, are a class of drugs that offset this effect, reducing the rapid pulse associated with palpitations, and decreasing tremor and anxiety. Thus, a person with hyperthyroidism can often obtain immediate temporary relief until the hyperthyroidism can be characterized with the Radioiodine test noted above, and more permanent treatment takes place. Note that these drugs do not treat hyperthyroidism or any of its long-term effects if left untreated, but rather, they treat or reduce only symptoms of the condition. Some minimal effect on thyroid hormone production also comes with propranolol, which has two roles in the treatment of hyperthyroidism, determined by the different isomers of propranolol. L-propranolol causes beta-blockade, thus treating the symptoms associated with hyperthyroidism, such as tremor, palpitations, anxiety, and heat intolerance. D-propranolol inhibits thyroxine deiodinase, thereby blocking the conversion of T4 to T3, providing some, though minimal, therapeutic effect. Other beta-blockers are used to treat only the symptoms associated with hyperthyroidism. Propranolol in the UK, and metoprolol in the US, are most frequently used to augment treatment for people with hyperthyroidism.
Travell preferred a 1.5-in hypodermic needle for trigger point therapy and used this needle for both injection therapy and dry needling. Travell never used an acupuncture needle. Travell had access to acupuncture needles but reasoned that they were far too thin for trigger point therapy. She preferred hypodermic needles because of their strength and tactile feedback: "A 22-gauge, 3.8-cm (1.5-in) needle is usually suitable for most superficial muscles. In hyperalgesic patients, a 25-gauge, 3.8-cm (1.5-in) needle may cause less discomfort, but will not provide the clear feeling of the structures being penetrated by the needle and is more likely to be deflected by the dense contraction knots that are the target... A 27-gauge needle, 3.8-cm (1.5-in) needle is even more flexible; the tip is more likely to be deflected by the contraction knots and it provides less tactile feedback for precision injection".
Bilawal Bhutto Zardari (born 21 September 1988) is a Pakistani politician who served as the 37th Minister of Foreign Affairs from 2022 to 2023. He became the chairman of the Pakistan People's Party in 2007 following his mother's assassination. Born in Karachi, Sindh, Bilawal maternally belongs to the Bhutto family and paternally to the Zardari family, he is the son of former Prime Minister Benazir Bhutto and President Asif Ali Zardari, and the grandson of former President Zulfikar Ali Bhutto. Bilawal Zardari was a member of the National Assembly of Pakistan from 2018 to 2023. He was re-elected as a Member of the National Assembly of Pakistan in the 2024 Pakistani general election from newly formed constituency NA-194 Larkana-I, taking oath in 2024.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.